Wegovy for Fatty Liver (MASH): The 2025 Approval Explained

    Wegovy for Fatty Liver (MASH): The 2025 Approval Explained

    Wegovy is FDA-approved for MASH with F2-F3 fibrosis. ESSENCE trial results, who qualifies, label dosing, Rezdiffra comparison and coverage.

    Written by Diana Gangan. Updated November 10, 2026.

    Yes, Wegovy is approved for a serious form of fatty liver disease: on August 15, 2025, the US Food and Drug Administration (FDA) approved Wegovy (semaglutide 2.4 mg) for adults with MASH, short for metabolic dysfunction-associated steatohepatitis, who have moderate to advanced liver scarring (fibrosis stages F2 to F3) but not cirrhosis. MASH is the newer name for NASH: fat in the liver plus inflammation and liver cell damage. The approval rests on the ESSENCE trial, in which 62.9% of people on semaglutide saw their MASH resolve without worse scarring after 72 weeks, compared with 34.3% on placebo. It is an accelerated approval, which means the FDA approved it based on liver biopsy results that are expected to predict real benefit, and Novo Nordisk must still prove in a longer trial that the drug prevents cirrhosis, liver failure and death. This guide explains the trial results, who qualifies, label dosing, how Wegovy compares with Rezdiffra, side effects, coverage, and approvals outside the US as of November 2026.

    Wegovy for Fatty Liver: The Short Answer

    1. 1Approved: FDA accelerated approval on August 15, 2025, for noncirrhotic MASH with F2 to F3 fibrosis in adults, alongside diet and exercise.
    2. 2Results: MASH resolution in 62.9% vs 34.3% on placebo, and fibrosis improvement in 36.8% vs 22.4%, at 72 weeks.
    3. 3Not yet confirmed: a 240-week outcomes trial is due to finish in June 2029; continued approval may depend on it.
    4. 4Who qualifies: doctors can use noninvasive scans and blood tests instead of a biopsy, according to 2025 AASLD guidance.
    5. 5Dose: the same 2.4 mg once-weekly maintenance dose used for weight management, reached by monthly steps.
    6. 6Not approved: in cirrhosis, or for simple fatty liver without MASH and fibrosis.

    What Did the FDA Approve Wegovy for in August 2025?

    The FDA approved Wegovy for "the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults," used with a reduced-calorie diet and more physical activity. Fibrosis is graded from F0 (no scarring) to F4 (cirrhosis), so F2 to F3 means significant scarring that has not yet reached cirrhosis. The approval was granted under the FDA's accelerated approval pathway, and the drug had earlier received breakthrough therapy designation, which speeds up review for serious conditions. The FDA estimates that about 6% of US adults, or 14.9 million people, have MASH; Novo Nordisk, the manufacturer, gives a higher estimate of about 22 million. This is a separate use from weight management, which is explained in what Wegovy does.

    What Is MASH, and How Is It Different From NASH, NAFLD and MASLD?

    In 2023 an international group of liver societies agreed new names for fatty liver disease that tie the condition to metabolic risk factors such as obesity, type 2 diabetes and high blood pressure. Under the new terms:

    1. 1MASLD (metabolic dysfunction-associated steatotic liver disease) replaces NAFLD. It means extra fat in the liver in someone with at least one metabolic risk factor.
    2. 2MASH (metabolic dysfunction-associated steatohepatitis) replaces NASH. It is the more serious, inflamed form of MASLD, in which liver cells are being damaged.
    3. 3Fibrosis is the scarring that can follow years of MASH.

    That is why searches for semaglutide for NASH and Wegovy for MASH describe the same thing. Wegovy's label materials themselves say "MASH, formerly NASH." The approval covers only MASH with F2 to F3 fibrosis, not every person with a fatty liver on an ultrasound.

    What Did the ESSENCE Trial Show?

    ESSENCE is the phase 3 trial behind the approval, published in the New England Journal of Medicine in 2025. It enrolled 1,197 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, who were randomly assigned 2 to 1 to weekly semaglutide 2.4 mg or placebo. The approval is based on part 1, an interim analysis of the first 800 participants (534 on semaglutide, 266 on placebo) after 72 weeks, when a second liver biopsy was taken.

    ESSENCE trial part 1: results at week 72 (Sanyal et al., NEJM 2025)

    Outcome
    Semaglutide 2.4 mg
    Placebo
    Difference (95% CI)

    MASH resolution without worsening of fibrosis

    62.9%

    34.3%

    28.7 points (21.1 to 36.2)

    Fibrosis improvement without worsening of MASH

    36.8%

    22.4%

    14.4 points (7.5 to 21.3)

    Both MASH resolution and fibrosis improvement

    32.7%

    16.1%

    Not shown here

    Average body weight change

    -10.5%

    -2.0%

    Not shown here

    In plain terms, about 6 in 10 people on semaglutide no longer met the biopsy definition of MASH, and a little over a third had less scarring, each measured with the other outcome not getting worse. The placebo group also improved noticeably, possibly because participants received lifestyle advice and regular care. Weight loss of about 10% may explain part of the liver benefit. Stomach and bowel side effects were more common with semaglutide. Novo Nordisk funded the trial. For how Wegovy affects heart outcomes, a separate question, see our guide to the SELECT cardiovascular trial.

    What Does Accelerated Approval Mean for Wegovy's Liver Indication?

    Accelerated approval lets the FDA approve a drug for a serious disease based on a "surrogate" result, here changes seen on a liver biopsy, that is reasonably likely to predict real clinical benefit, before that benefit has been shown. The FDA's approval letter grants it under Subpart H (21 CFR 314.510) and requires a confirmatory trial. The label says continued approval "may be contingent upon the verification and description of clinical benefit in a confirmatory trial."

    1. 1The trial: part 2 of ESSENCE (trial NN9931-4553), lasting 240 weeks, about 4.6 years.
    2. 2What it measures: a combined outcome of progression to cirrhosis, liver failure (hepatic decompensation), liver transplant and death.
    3. 3Deadlines set by the FDA: trial completion by June 2029 and final report by December 2029.

    So, as of November 2026, Wegovy has been shown to improve liver tissue, but it has not yet been shown to prevent cirrhosis or death from liver disease.

    Who Qualifies for Wegovy for MASH?

    Under the label, candidates are adults with MASH and F2 to F3 fibrosis who do not have cirrhosis. Because biopsies are invasive, the American Association for the Study of Liver Diseases (AASLD) issued updated guidance in November 2025 saying a biopsy is not required. Doctors can instead use noninvasive tests (NITs): a FibroScan-type liver stiffness scan (VCTE), magnetic resonance elastography (MRE), or the ELF blood test.

    AASLD 2025 noninvasive test ranges for semaglutide in MASH

    Test
    Eligible range (likely F2 to F3)
    Gray zone (individual decision)
    Suggests cirrhosis (not approved)

    VCTE (liver stiffness scan)

    8 to 15 kPa

    15 to 20 kPa

    Over 20 kPa

    MRE (MRI elastography)

    3.1 to 4.4 kPa

    4.4 to 5.0 kPa

    Over 5.0 kPa

    ELF blood test

    9.2 to 10.5

    10.5 to 11.3

    Over 11.3

    In the gray zone, AASLD advises treating only after an individualized decision and once cirrhosis has been ruled out. AASLD also notes that no noninvasive test predicts how a given person will respond, and it recommends liver blood panels only when clinically needed rather than on a fixed schedule.

    How Is Wegovy Dosed for MASH?

    The label uses the same schedule as Wegovy's other uses. Treatment starts at 0.25 mg injected under the skin once a week, and the dose is raised every 4 weeks until the 2.4 mg once-weekly maintenance dose is reached. If a step is not tolerated, the next increase can be delayed by 4 weeks. If 2.4 mg is not tolerated, the dose can be lowered to 1.7 mg weekly, and a return to 2.4 mg can be considered later. Wegovy should not be combined with other semaglutide products or other GLP-1 receptor agonists. The step-by-step schedule is in our Wegovy dosing schedule guide, and more on the target dose is in Wegovy maintenance dose.

    Only the 2.4 mg injection is labeled for MASH. We found no source showing that the higher-dose Wegovy HD 7.2 mg or the oral Wegovy pill is approved for this use; differences between the two forms are covered in Wegovy pill vs injection.

    Wegovy vs Rezdiffra: How Do They Compare?

    Rezdiffra (resmetirom), from Madrigal Pharmaceuticals, was approved for this condition earlier, receiving FDA accelerated approval on March 14, 2024, for noncirrhotic NASH with F2 to F3 fibrosis. It is a once-daily pill that works directly on the liver by activating thyroid hormone receptor beta, which increases fat burning in liver cells. Wegovy, by contrast, is a weekly GLP-1 injection that reduces appetite and body weight. The two have never been compared head to head, and the figures below come from different trials that should not be compared directly.

    Wegovy and Rezdiffra for MASH: separate trials, not head to head

    Feature
    Wegovy (semaglutide)
    Rezdiffra (resmetirom)

    How it works

    GLP-1 receptor agonist; lowers appetite and weight

    THR-beta agonist; acts on liver fat metabolism

    How it is taken

    Injection once a week

    Tablet once a day

    FDA accelerated approval

    August 15, 2025

    March 14, 2024

    Label dose

    2.4 mg weekly (1.7 mg if needed)

    80 mg under 100 kg; 100 mg at 100 kg or more

    Key trial and timepoint

    ESSENCE, 72 weeks

    MAESTRO-NASH, 52 weeks

    MASH/NASH resolution vs placebo

    62.9% vs 34.3%

    25.9% (80 mg) and 29.9% (100 mg) vs 9.7%

    Fibrosis improvement vs placebo

    36.8% vs 22.4%

    24.2% (80 mg) and 25.9% (100 mg) vs 14.2%

    The trials differed in length (72 vs 52 weeks), in the patients enrolled, and in how much the placebo groups improved, so the higher percentages for Wegovy do not show it is the better drug.

    Can Wegovy and Rezdiffra Be Used Together?

    Using semaglutide and resmetirom together has not been studied, according to the 2025 AASLD guidance. Whether combining them adds benefit or raises risk is unknown.

    What Are the Side Effects, and Who Should Not Take It?

    The side effects are the same as for Wegovy's other uses. The most common are nausea, diarrhea, vomiting, constipation and stomach pain, which are usually worst during dose increases. The label also includes:

    1. 1A boxed warning about thyroid C-cell tumors seen in rodents; Wegovy should not be used by people with a personal or family history of medullary thyroid cancer or with multiple endocrine neoplasia syndrome type 2 (MEN 2).
    2. 2Warnings about pancreatitis (inflammation of the pancreas) and gallbladder disease, including gallstones.
    3. 3Not approved for people with cirrhosis from MASH.

    What is known about longer-term use is summarized in GLP-1 long-term side effects, and typical weight change on Wegovy is covered in how much weight you can lose on Wegovy.

    Will Insurance or Medicare Cover Wegovy for Fatty Liver?

    Coverage depends on your plan. Because MASH is a medical indication separate from weight loss, some plans that exclude weight-loss drugs may consider Wegovy for MASH, usually with prior authorization requiring proof of F2 to F3 fibrosis and no cirrhosis. As one example, Mississippi Medicaid has published prior-authorization criteria for Wegovy in MASH. Medicare Part D coverage varies by plan, and we could not confirm the details in a government source, so check your plan's formulary directly. General coverage questions are covered in does insurance cover Wegovy.

    At approval in August 2025, Wegovy's list price was $1,349 a month. Self-pay prices have changed since then, so check current manufacturer pricing and savings programs; options are summarized in our Wegovy cost and savings card guide.

    Is Semaglutide Approved for MASH Outside the US?

    1. 1European Union: semaglutide for MASH is sold under the brand name Kayshild. It received a positive CHMP opinion on January 29, 2026, and a conditional marketing authorisation on March 26, 2026.
    2. 2United Kingdom: the MHRA granted conditional authorisation on July 3, 2026. As of November 2026 it is not yet available on the NHS for MASH while a NICE appraisal is pending.

    Like the US approval, both European authorisations are conditional on further evidence.

    When to Talk to Your Doctor

    1. 1You have been told you have fatty liver and also have type 2 diabetes, obesity or high blood pressure, which raise the risk of MASH and scarring.
    2. 2Blood tests show raised liver enzymes, or a FibroScan or ELF result suggests fibrosis.
    3. 3You already take Wegovy for weight and want to know whether it is also treating your liver.
    4. 4You develop severe stomach pain that spreads to your back, yellowing of the skin or eyes, or signs of gallbladder problems while on treatment.
    5. 5You notice symptoms of advanced liver disease, such as swelling of the belly or legs, confusion, or vomiting blood; seek urgent care.

    Questions to Ask Your Doctor

    1. 1Do I have simple fatty liver (MASLD) or MASH, and what stage is my fibrosis?
    2. 2Which noninvasive test (FibroScan, MRE or ELF) should I have, and do I need a biopsy?
    3. 3Have you ruled out cirrhosis?
    4. 4Is Wegovy or Rezdiffra a better fit for me, and why?
    5. 5How will we check whether treatment is working, and how often?
    6. 6Will my insurance cover Wegovy for MASH, and is prior authorization needed?

    The Bottom Line

    Wegovy is FDA-approved, under accelerated approval, for adults with MASH and F2 to F3 liver fibrosis who do not have cirrhosis. In the ESSENCE trial it resolved MASH in about 63% of people and improved scarring in about 37% after 72 weeks, well above placebo, at the same 2.4 mg weekly dose used for weight management. What it has not yet shown is that it prevents cirrhosis, liver failure or death; that answer is expected from a confirmatory trial due in 2029. If you have fatty liver with metabolic risk factors, ask your doctor about fibrosis testing to find out whether you are a candidate.

    FAQ

    Wegovy is approved for MASH, the inflamed form of fatty liver disease, in adults with F2 to F3 fibrosis and no cirrhosis. It is not approved for simple fatty liver without MASH and scarring.

    In the ESSENCE trial, 36.8% of people on Wegovy had at least some improvement in fibrosis after 72 weeks, compared with 22.4% on placebo. Most people did not have measurable fibrosis improvement in that time.

    No. The MASH approval covers only noncirrhotic disease. AASLD guidance says cirrhosis is suggested by a liver stiffness over 20 kPa, MRE over 5.0 kPa or ELF over 11.3.

    Not necessarily. The 2025 AASLD guidance says candidates can be identified with noninvasive tests such as a FibroScan, MRE or ELF blood test, although your insurer may have its own requirements.

    It depends on the Part D plan. We could not confirm Medicare's rules in a government source as of November 2026, so ask your plan whether Wegovy for MASH is on its formulary and needs prior authorization.

    We found no source showing a MASH approval for Ozempic. Wegovy is the semaglutide product approved for MASH in the US.

    Sources

    This article summarizes published research and regulatory documents for general information and is not medical advice. The ESSENCE trial was funded by Novo Nordisk, the maker of Wegovy.

    Diana Gangan

    Author

    Published November 9, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    GLP-1 Drugs Explained: Types, Benefits, Risks, and How They Help With Weight Loss